CS
ALLO icon

Credit Suisse’s Allogene Therapeutics ALLO Stock Holding History

Credit Suisse’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$418K Buy
93,461
+17,301
+23% +$72.2K ﹤0.01% 2712
2023
Q4 		$244K Sell
76,160
-8,982
-11% -$25.5K ﹤0.01% 2947
2023
Q3 		$270K Sell
85,142
-34,373
-29% -$151K ﹤0.01% 2963
2023
Q2 		$594K Buy
119,515
+13,675
+13% +$74K ﹤0.01% 2686
2023
Q1 		$523K Buy
105,840
+3,415
+3% +$21.9K ﹤0.01% 2734
2022
Q4 		$644K Buy
102,425
+20,108
+24% +$186K ﹤0.01% 2620
2022
Q3 		$889K Buy
82,317
+926
+1% +$12.6K ﹤0.01% 2414
2022
Q2 		$929K Buy
81,391
+13,898
+21% +$123K ﹤0.01% 2444
2022
Q1 		$615K Buy
67,493
+2,825
+4% +$29.4K ﹤0.01% 2851
2021
Q4 		$965K Sell
64,668
-13,399
-17% -$236K ﹤0.01% 3346
2021
Q3 		$2.01M Buy
78,067
+4,095
+6% +$97.2K ﹤0.01% 2816
2021
Q2 		$1.93M Buy
73,972
+11,683
+19% +$333K ﹤0.01% 2895
2021
Q1 		$2.2M Sell
62,289
-69,875
-53% -$2.36M ﹤0.01% 2739
2020
Q4 		$3.34M Buy
132,164
+15,797
+14% +$515K ﹤0.01% 2417
2020
Q3 		$4.39M Sell
116,367
-5,245
-4% -$198K ﹤0.01% 1877
2020
Q2 		$5.21M Buy
121,612
+47,806
+65% +$1.73M ﹤0.01% 1684
2020
Q1 		$1.43M Sell
73,806
-55,936
-43% -$1.33M ﹤0.01% 2369
2019
Q4 		$3.37M Buy
129,742
+110,462
+573% +$3.04M ﹤0.01% 2185
2019
Q3 		$525K Buy
19,280
+5,319
+38% +$151K ﹤0.01% 3413
2019
Q2 		$374K Buy
+13,961
New +$389K ﹤0.01% 3569

Other funds holding ALLO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Credit Suisse's ALLO Position: Q1 2024 in Review

Credit Suisse increased its Allogene Therapeutics (ALLO) stake by 23% in Q1 2024, buying an estimated $72.2K and bringing the position to 93,461 shares worth $418K. The position accounts for ﹤0.01% of the portfolio, ranked #2712.

Credit Suisse first reported a position in ALLO in Q2 2019 and has held it in 20 quarters since. The position peaked at $5.21M in Q2 2020. 161 funds tracked by Wall St. Rank hold ALLO as of Q1 2024.

  • Credit Suisse held 93,461 shares of Allogene Therapeutics worth $418K as of Q1 2024.
  • Credit Suisse bought 17,301 Allogene Therapeutics shares in Q1 2024, an estimated $72.2K.
  • Allogene Therapeutics made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #2712 holding.
  • Credit Suisse first reported a position in Allogene Therapeutics in Q2 2019 and has held it in 20 quarters since.
  • Credit Suisse's Allogene Therapeutics position peaked at $5.21M in Q2 2020.
  • 161 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.